

K993954

JAN 11 2000



Summary of Safety & Effectiveness  
SYNCHRON® Systems Multi-Drug  
DAT Low and High Urine Calibrators

1.0 **Submitted By:**

Lucinda Stockert  
Staff Regulatory Specialist, Product Submissions  
Beckman Coulter, Inc.  
200 S. Kraemer Blvd., W-104  
Brea, California 92822-8000  
Telephone: (714) 961-3777  
FAX: (714) 961-4123

2.0 **Date Submitted:**

November 16, 1999

3.0 **Device Name(s):**

3.1 **Proprietary Names**

SYNCHRON® Systems Multi-Drug DAT Low and High Urine Calibrators

3.2 **Classification Name**

Calibrator, Drug Mixture (21 CFR §862.3200)

4.0 **Predicate Device(s):**

SYNCHRON Systems Reagent	Predicate	Manufacturer	Docket Number
SYNCHRON® Systems Multi-Drug DAT Low and High Urine Calibrators	Multi-Drug Urine Calibrators	Diagnostic Reagents, Inc.*	K983159

\*Diagnostic Reagents, Inc. Sunnyvale, CA

5.0 **Description:**

The SYNCHRON® Systems Multi-Drug DAT Low and High Urine Calibrators are ready-to-use human urine-based calibrator materials.

Beckman Coulter, Inc.  
200 S. Kraemer Boulevard  
Brea, CA 92821

Mailing Address:  
200 S. Kraemer Boulevard  
P.O. Box 8000  
Brea, CA 92822-8000

Telephone: (714) 993-5321  
Facsimile: (714) 961-4165  
Internet: [www.beckmancoulter.com](http://www.beckmancoulter.com)

5.0 **Intended Use:**

The SYNCHRON® Systems DAT Multi-Drug Low and High Urine Calibrators, in conjunction with SYNCHRON Reagents, are intended for use on SYNCHRON Systems for calibration of Amphetamines, Barbiturates, Benzodiazepine, Cocaine Metabolite, Methadone, Methaqualone, Opiate 2000 ng, Phencyclidine, and Propoxyphene enzyme immunoassays.

7.0 **Comparison to Predicate(s):**

Identical to predicate product but labeled for Beckman Coulter, Inc.

8.0 **Summary of Performance Data:**

The data in the Premarket Notification on safety and effectiveness supports a finding of substantial equivalence to toxicology calibrators already in commercial distribution. Stress stability studies of the DAT Multi-Drug Low and High Urine Calibrators support the Beckman stability claim of 12 months.

This summary of safety and effectiveness is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and the implementing regulation 21 CFR 807.92.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

**JAN 11 2000**

Ms. Lucinda Stockert  
Staff Regulatory Specialist  
Beckman Coulter, Inc.  
200 S. Kraemer Boulevard  
M/S W-104  
Box 8000  
Brea, California 92822-8000

Re: K993954  
Trade Name: SYNCHRON® Systems DAT Multi-Drug Low and High Urine Calibrators  
Regulatory Class: II  
Product Code: DKB  
Dated: November 16, 1999  
Received: November 22, 1999

Dear Ms. Stockert:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895.

A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.


Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,



Steven I. Gutman, M.D, M.B.A.  
Director  
Division of Clinical  
Laboratory Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

510(k) Number (if known): ~~Not yet assigned~~ K993954

Device Name: SYNCHRON® Systems DAT Multi-Drug Low and High Urine Calibrators

Indications for Use:

The SYNCHRON® Systems DAT Multi-Drug Low and High Urine Calibrators, in conjunction with SYNCHRON Reagents, are intended for use on SYNCHRON Systems for calibration of Amphetamines, Barbiturates, Benzodiazepine, Cocaine Metabolite, Methadone, Methaqualone, Opiate 2000 ng, Phencyclidine, and Propoxyphene enzyme immunoassays.

**21 CFR 862.3200 Calibrators, Drug Mixture**

**(a) Identification.** A clinical toxicology calibrator is a device intended for medical purposes for use in a test system to establish points of reference that are used in the determination of values in the measurement of substances in human specimens. A clinical toxicology calibrator can be a mixture of drugs or a specific material for a particular drug.

**(b) Classification.** Class II.

Jean Cooper  
(Division Sign-Off)  
Division of Clinical Laboratory Devices  
510(k) Number K 993954

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

*Concurrence of CDRH, Office of Device Evaluation (ODE)*

Prescription Use ✓  
(per 21 CFR 801.109)

OR

Over-the-Counter Use \_\_\_\_\_  
Optional Format 1-2-96